DK1082293T3 - Formoterol-polymorfer - Google Patents
Formoterol-polymorferInfo
- Publication number
- DK1082293T3 DK1082293T3 DK99968848T DK99968848T DK1082293T3 DK 1082293 T3 DK1082293 T3 DK 1082293T3 DK 99968848 T DK99968848 T DK 99968848T DK 99968848 T DK99968848 T DK 99968848T DK 1082293 T3 DK1082293 T3 DK 1082293T3
- Authority
- DK
- Denmark
- Prior art keywords
- formoterol
- optically pure
- polymorphs
- disclosed
- benzeneethanamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C217/86—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/083,010 US6040344A (en) | 1996-11-11 | 1998-05-21 | Formoterol process |
PCT/US1999/025371 WO2000021487A2 (en) | 1998-05-21 | 1999-05-20 | Formoterol polymorphs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1082293T3 true DK1082293T3 (da) | 2004-06-21 |
Family
ID=22175359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99968848T DK1082293T3 (da) | 1998-05-21 | 1999-05-20 | Formoterol-polymorfer |
Country Status (10)
Country | Link |
---|---|
US (2) | US6040344A (da) |
EP (1) | EP1082293B1 (da) |
JP (1) | JP2002527364A (da) |
AT (1) | ATE259779T1 (da) |
CA (1) | CA2333004C (da) |
DE (1) | DE69914898T2 (da) |
DK (1) | DK1082293T3 (da) |
ES (1) | ES2216632T3 (da) |
PT (1) | PT1082293E (da) |
WO (1) | WO2000021487A2 (da) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713651B1 (en) * | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
BR0013935A (pt) * | 1999-09-13 | 2002-05-14 | Bridge Pharma Inc | IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos |
UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
US6666774B2 (en) * | 2000-07-27 | 2003-12-23 | Attitude Technology, Inc. | Billiard equipment |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US7659225B2 (en) * | 2001-09-17 | 2010-02-09 | Basf Catalysts Llc | Precious metal catalyst for debenzylation |
US6992037B2 (en) * | 2001-09-17 | 2006-01-31 | Engelhard Corporation | Precious metal catalyst for debenzylation |
US6472563B1 (en) | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
WO2003042160A1 (en) * | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
ATE465712T1 (de) * | 2002-03-01 | 2010-05-15 | Chiesi Farma Spa | Ultrafeine zusammensetzungen von formoterol |
EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
AU2003295695B2 (en) | 2002-12-10 | 2009-08-20 | Sepracor Inc. | Levalbuterol salt |
PT1572217E (pt) | 2002-12-12 | 2008-11-28 | Nycomed Gmbh | Medicamento combinado de r,r-formoterol e ciclesonida |
EP1587482A4 (en) * | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | ANTI-INFLAMMATORY COMPOSITIONS AND USES THEREOF |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
EP1615881A2 (en) * | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
US7358244B2 (en) * | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
GB0315889D0 (en) * | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
PL1670482T5 (pl) | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
CA2561400A1 (en) * | 2004-04-02 | 2005-10-13 | Glaxo Group Limited | Chemical process and new crystalline form |
WO2005097095A1 (en) * | 2004-04-05 | 2005-10-20 | Sepracor Inc. | (r,r)-formoterol in combination with other pharmacological agents |
US8134010B2 (en) * | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
US7968575B2 (en) * | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
EP1753734A1 (en) * | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
US20080039495A1 (en) * | 2004-06-03 | 2008-02-14 | Linsell Martin S | Diamine Beta2 Adrenergic Receptor Agonists |
US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
JP2008512470A (ja) | 2004-09-10 | 2008-04-24 | セラヴァンス, インコーポレーテッド | アミジン置換アリールアニリン化合物 |
US20060120972A1 (en) * | 2004-11-09 | 2006-06-08 | Peter Engels | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension |
US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
US7718822B2 (en) * | 2007-08-28 | 2010-05-18 | Sepracor Inc. | Carbamate Stereoisomer |
US8501994B2 (en) | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
CN101393186A (zh) * | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | 一种hplc法分离分析酒石酸福莫特罗手性异构体的方法 |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
EP2257172A4 (en) * | 2008-02-26 | 2013-07-03 | Elevation Pharmaceuticals Inc | METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION |
EP2262479A2 (en) * | 2008-02-28 | 2010-12-22 | Actavis Group PTC ehf. | Amorphous arformoterol l-(+)-tartrate |
WO2009147383A1 (en) * | 2008-06-02 | 2009-12-10 | Cipla Limited | Process for the synthesis of arformoterol |
US20090306215A1 (en) * | 2008-06-10 | 2009-12-10 | Protia, Llc | Deuterium-enriched arformoterol |
WO2010128355A2 (en) | 2008-12-26 | 2010-11-11 | Actavis Group Ptc Ehf | Improved processes for preparing substantially pure arformoterol and its intermediates |
CN104523661A (zh) * | 2009-02-06 | 2015-04-22 | 南加利福尼亚大学 | 含有单萜的治疗组合物 |
CN101531597B (zh) * | 2009-04-01 | 2013-03-06 | 杭州师范大学 | 3-硝基-4-苄氧基-α-溴代苯乙酮的新型合成方法 |
TWI695723B (zh) | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
CA2764867C (en) * | 2009-06-09 | 2016-05-17 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
CN101921200B (zh) * | 2009-06-16 | 2014-01-15 | 上海医药工业研究院 | 一种n-苄基-1-(4-甲氧基苯基)-2-丙胺的制备方法 |
SI2453894T1 (sl) | 2009-07-15 | 2016-02-29 | Theravance Biopharma R&D Ip, Llc | Kristalinična oblika proste baze bifenilne spojine |
EP2477642A4 (en) * | 2009-09-17 | 2013-03-13 | Mutual Pharmaceutical Co | METHOD FOR THE TREATMENT OF ASTHMA WITH ANTIVIRUS AGENTS |
EP2348013A1 (en) | 2010-01-25 | 2011-07-27 | Inke, S.A. | Process for preparation of intermediates of arformoterol |
CN104744215B (zh) | 2010-03-03 | 2019-03-15 | 尼昂克技术公司 | 包含单萜的药物组合物 |
CN102199098B (zh) * | 2010-03-22 | 2013-07-31 | 中山大学 | 一种合成(r)-n-苄基-1-(4-甲氧基苯基)-2-丙胺的方法及其应用 |
CN110464718A (zh) | 2010-08-27 | 2019-11-19 | 尼昂克技术公司 | 包含poh衍生物的药物组合物 |
US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
CN103517892B (zh) | 2010-12-17 | 2016-01-27 | 尼昂克技术公司 | 使用异紫苏醇的方法和装置 |
WO2013136061A1 (en) | 2012-03-12 | 2013-09-19 | Laboratorios Lesvi, S.L. | New polymorphic form of a long-acting beta-2 adrenoceptor agonist |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
ES2699257T3 (es) | 2013-02-28 | 2019-02-08 | Dermira Inc | Sales de glicopirrolato |
PT2968312T (pt) | 2013-03-15 | 2018-04-19 | Verona Pharma Plc | Combinação de fármacos |
US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
US9499475B2 (en) | 2013-05-17 | 2016-11-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of arformoterol or salt thereof |
JP2016519160A (ja) | 2013-05-22 | 2016-06-30 | パール セラピューティクス,インコーポレイテッド | 3つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム |
CN103772289B (zh) * | 2014-01-03 | 2016-02-17 | 湖南迪诺制药有限公司 | 合成塞克硝唑的方法及塞克硝唑 |
HUE048020T2 (hu) | 2014-05-12 | 2020-05-28 | Verona Pharma Plc | Új kezelés |
AU2016219257B2 (en) | 2015-02-12 | 2020-06-25 | University Of Southern California | Pharmaceutical compositions comprising perillyl alcohol derivatives |
US10858305B2 (en) | 2016-11-30 | 2020-12-08 | Neonc Technologies, Inc. | Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer |
BR112020016074A2 (pt) | 2018-02-08 | 2020-12-08 | Neonc Technologies, Inc | Métodos de permeabilização da barreira hematoencefálica |
CN110627673B (zh) * | 2018-06-22 | 2023-04-07 | 上海天慈中商药业有限公司 | 一种福莫特罗关键中间体的制备方法 |
US11826382B2 (en) | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
US11642372B2 (en) * | 2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
CN111909049B (zh) * | 2020-09-03 | 2023-04-25 | 扬州中宝药业股份有限公司 | 一种酒石酸阿福特罗精制的方法 |
CN112745234A (zh) * | 2020-12-31 | 2021-05-04 | 河北化工医药职业技术学院 | 利用非环原子上连接羟基的单环不饱和化合物制备双手性中心药物的方法 |
KR20240042438A (ko) | 2021-07-09 | 2024-04-02 | 아스트라제네카 파마수티컬스 엘피 | 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템 |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
ES2005492A6 (es) * | 1987-12-23 | 1989-03-01 | Lasa Lab | Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i). |
ES2031407A6 (es) * | 1988-10-05 | 1992-12-01 | Lasa Lab | Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida". |
SE8901060D0 (sv) * | 1989-03-28 | 1989-03-28 | Draco Ab | New compounds |
SE9003057D0 (sv) * | 1990-09-26 | 1990-09-26 | Astra Ab | New process |
ES2208772T3 (es) * | 1996-01-10 | 2004-06-16 | Asahi Kasei Kabushiki Kaisha | Nuevos compuestos triciclicos y compuestos farmaceuticos que contienen los mismos. |
WO1998021175A1 (en) * | 1996-11-11 | 1998-05-22 | Sepracor, Inc. | Process for the preparation of optically pure isomers of formoterol |
ATE215820T1 (de) * | 1997-10-08 | 2002-04-15 | Sepracor Inc | Dosierungsform zur verabreichung von aerosolen |
-
1998
- 1998-05-21 US US09/083,010 patent/US6040344A/en not_active Expired - Lifetime
-
1999
- 1999-05-20 EP EP99968848A patent/EP1082293B1/en not_active Expired - Lifetime
- 1999-05-20 DE DE69914898T patent/DE69914898T2/de not_active Expired - Lifetime
- 1999-05-20 DK DK99968848T patent/DK1082293T3/da active
- 1999-05-20 WO PCT/US1999/025371 patent/WO2000021487A2/en active IP Right Grant
- 1999-05-20 ES ES99968848T patent/ES2216632T3/es not_active Expired - Lifetime
- 1999-05-20 JP JP2000575463A patent/JP2002527364A/ja active Pending
- 1999-05-20 CA CA002333004A patent/CA2333004C/en not_active Expired - Lifetime
- 1999-05-20 AT AT99968848T patent/ATE259779T1/de active
- 1999-05-20 PT PT99968848T patent/PT1082293E/pt unknown
-
2000
- 2000-01-27 US US09/493,042 patent/US6268533B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69914898D1 (en) | 2004-03-25 |
ATE259779T1 (de) | 2004-03-15 |
ES2216632T3 (es) | 2004-10-16 |
CA2333004A1 (en) | 2000-04-20 |
US6040344A (en) | 2000-03-21 |
JP2002527364A (ja) | 2002-08-27 |
EP1082293A2 (en) | 2001-03-14 |
WO2000021487A2 (en) | 2000-04-20 |
EP1082293B1 (en) | 2004-02-18 |
WO2000021487A3 (en) | 2000-07-13 |
PT1082293E (pt) | 2004-07-30 |
DE69914898T2 (de) | 2004-12-09 |
CA2333004C (en) | 2009-08-18 |
US6268533B1 (en) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1082293T3 (da) | Formoterol-polymorfer | |
ES2178015T3 (es) | Procedimiento de preparacion de isomeros de formoterol opticamente puros. | |
RU94042903A (ru) | 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция | |
RU94036748A (ru) | Церамиды, способ их получения, композиция на их основе и способ гидратирующей обработки кожи или волос | |
CA2200707A1 (en) | Novel prostaglandin synthase inhibitors | |
ES485621A1 (es) | Un procedimiento para la preparacion de derivados de diben- zopirano | |
FI906438A0 (fi) | Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi | |
AU7725596A (en) | Antithrombotic diamines | |
CY1112139T1 (el) | Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης | |
NO20053089D0 (no) | Carbamidsyreestere med anticolinergisk virkning. | |
DE69738154D1 (de) | Optische auflösung von methylphenidat mittels 0,0'-bisaroyl-weinsäuren | |
BR0016847A (pt) | Composições fluidas contendo éster | |
PT1349828E (pt) | Processo para a preparacao de isomeros de salutamol | |
NO20040388L (no) | Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten | |
DK0938584T3 (da) | Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre | |
ES2196783T3 (es) | Nuevo procedimiento de preparacion de la fexofenadina. | |
BR9811252A (pt) | Processo para preparação de compostos farmacêuticos | |
ID27440A (id) | Proses untuk menyiapkan penengah-penengah | |
PT1347960E (pt) | Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina | |
NO940113L (no) | Syntese av 2-fenyl-substituerte 1,3-propandioler | |
HUP0004510A1 (hu) | Eljárás L-dihidroorotsav előállítására és a vegyület alkalmazása | |
TW332205B (en) | A process for making a clinically efficacious HIV protease inhibitor eliminates one step in its synthesis, by an alternative convergent synthesis using 2(S)-4-picolyl-2-piperazine-t-butyl-carboxamide as an intermediate. | |
EP0816328A3 (en) | Process for the manufacture of acetonylbenzamides | |
ATE295728T1 (de) | Herstellung von 3-fluoroxindolderivaten | |
DE69019591D1 (de) | Phospholipase-A2-Inhibitor, Verfahren zu seiner Herstellung und diesen enthaltende pharmazeutische oder veterinäre Zusammensetzungen. |